AMTB vs MCBS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMTB exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating stable but not strong fundamentals. The absence of an Altman Z-Score prevents a full distress risk assessment, though the Price/Book of 0.93 suggests the stock trades below tangible book value. Strong revenue growth of 576.5% YoY and a low forward P/E of 7.88 signal potential value, but weak ROA of 0.64% and inconsistent earnings surprises temper optimism. Analysts recommend a 'buy' with a $22.75 target, implying modest upside from current levels.
MCBS presents a classic value-trap profile: fundamentally undervalued but showing signs of deteriorating financial health. While the current price of $31.08 sits below both the Graham Number ($33.49) and the Intrinsic Value ($51.35), the Piotroski F-Score of 3/9 indicates weak financial health. Strong revenue growth (24.3%) and a consistent earnings beat record are offset by a severely bearish technical trend (10/100) and low insider sentiment (40/100).
Compare Another Pair
Related Comparisons
AMTB vs MCBS: Head-to-Head Comparison
This page compares Amerant Bancorp Inc. (AMTB) and MetroCity Bankshares, Inc. (MCBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.